Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy
Objective: The aim of this study was to evaluate the activity and tolerability of docetaxel in patients with hormone-resistant prostate cancer previously exposed to chemotherapy. Methods: We enrolled 27 patients with hormone-resistant prostatic cancer that had progressed during first-line chemothera...
Gespeichert in:
| Veröffentlicht in: | Oncology 2003-01, Vol.64 (4), p.300-305 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 305 |
|---|---|
| container_issue | 4 |
| container_start_page | 300 |
| container_title | Oncology |
| container_volume | 64 |
| creator | Petrioli, Roberto Pozzessere, Daniele Messinese, Simona Sabatino, Marianna Di Palma, Teresa Marsili, Stefania Correale, Pierpaolo Manganelli, Antonio Salvestrini, Francesco Francini, Guido |
| description | Objective: The aim of this study was to evaluate the activity and tolerability of docetaxel in patients with hormone-resistant prostate cancer previously exposed to chemotherapy. Methods: We enrolled 27 patients with hormone-resistant prostatic cancer that had progressed during first-line chemotherapy. The primary end-point was palliative response defined as a 2-point reduction in the 6-point present pain intensity scale, and an improvement in Karnofsky performance status of one 10-point category. The treatment consisted of weekly docetaxel 25 mg/m² body surface area administered by means of a 1-hour intravenous infusion with corticosteroid premedication. Results: The primary criterion of palliative response was met in 13 patients (48%) after eight treatment cycles; its median duration was 6 months (range 1–8). Mean global quality of life improved in 8 and 10 patients after respectively four and eight treatment cycles. After a median follow-up of 8 months, 21 patients had died: the median survival was 9+ months (range 2–18). Weekly docetaxel was very well tolerated: grade 3 neutropenia occurred in 1 patient and grade 3 anemia in 2. Conclusions: Weekly low-dose docetaxel is an effective and well-tolerated treatment for patients with hormone-resistant prostate cancer previously exposed to chemotherapy. |
| doi_str_mv | 10.1159/000070285 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_70285</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>669586331</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-eccfe6533829e3b793030a2148dac318f25bc4eb619f62e9d4f71d6f550b3d7a3</originalsourceid><addsrcrecordid>eNpt0EtrGzEUBWBREhrX7aLrQBCGLrKYVM95LMPkCYaE0tLloJGukvFjNJVkN_73kWMn2UQbCe7HEfcg9J2SM0pl9ZOkUxBWyk9oRAXjGWGcHaARIZxkTFBxhL6EMNsqKfLP6IiyQlaSiREKfwHmiw2euv_ZhQuAL5yGqJ5ggbsen5u16jUYfOP80vWQ_YLQhaj6iO-9S48IuN4Kj-9V7KCPIQ1g3blVSKGXT0OKNDg6XD_C0sVH8GrYfEWHVi0CfNvfY_Tn6vJ3fZNN765v6_NppnkpYwZaW8gl5yWrgLdFxdM6ilFRGqU5LS2TrRbQ5rSyOYPKCFtQk1spSctNofgYTXa5g3f_VhBiM3Mr36cvG8ZIKVhBZUKnO6TTQsGDbQbfLZXfNJQ023abt3aTPdkHrtolmHe5rzOBH3ugglYL61M3XXh3ohBVlRYZo-Odmyv_AP4NvH4z-XB6V09fQDMYy58B-kuWlw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220842715</pqid></control><display><type>article</type><title>Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy</title><source>Karger Journals</source><source>MEDLINE</source><creator>Petrioli, Roberto ; Pozzessere, Daniele ; Messinese, Simona ; Sabatino, Marianna ; Di Palma, Teresa ; Marsili, Stefania ; Correale, Pierpaolo ; Manganelli, Antonio ; Salvestrini, Francesco ; Francini, Guido</creator><creatorcontrib>Petrioli, Roberto ; Pozzessere, Daniele ; Messinese, Simona ; Sabatino, Marianna ; Di Palma, Teresa ; Marsili, Stefania ; Correale, Pierpaolo ; Manganelli, Antonio ; Salvestrini, Francesco ; Francini, Guido</creatorcontrib><description>Objective: The aim of this study was to evaluate the activity and tolerability of docetaxel in patients with hormone-resistant prostate cancer previously exposed to chemotherapy. Methods: We enrolled 27 patients with hormone-resistant prostatic cancer that had progressed during first-line chemotherapy. The primary end-point was palliative response defined as a 2-point reduction in the 6-point present pain intensity scale, and an improvement in Karnofsky performance status of one 10-point category. The treatment consisted of weekly docetaxel 25 mg/m² body surface area administered by means of a 1-hour intravenous infusion with corticosteroid premedication. Results: The primary criterion of palliative response was met in 13 patients (48%) after eight treatment cycles; its median duration was 6 months (range 1–8). Mean global quality of life improved in 8 and 10 patients after respectively four and eight treatment cycles. After a median follow-up of 8 months, 21 patients had died: the median survival was 9+ months (range 2–18). Weekly docetaxel was very well tolerated: grade 3 neutropenia occurred in 1 patient and grade 3 anemia in 2. Conclusions: Weekly low-dose docetaxel is an effective and well-tolerated treatment for patients with hormone-resistant prostate cancer previously exposed to chemotherapy.</description><identifier>ISSN: 0030-2414</identifier><identifier>EISSN: 1423-0232</identifier><identifier>DOI: 10.1159/000070285</identifier><identifier>PMID: 12759524</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Aged ; Antineoplastic agents ; Antineoplastic Agents, Phytogenic - administration & dosage ; Antineoplastic Agents, Phytogenic - adverse effects ; Biological and medical sciences ; Chemotherapy ; Clinical Study ; Drug Administration Schedule ; Humans ; Infusions, Intravenous ; Male ; Medical sciences ; Middle Aged ; Paclitaxel - administration & dosage ; Paclitaxel - adverse effects ; Paclitaxel - analogs & derivatives ; Palliative Care - methods ; Pharmacology. Drug treatments ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - pathology ; Quality of Life ; Taxoids ; Treatment Outcome</subject><ispartof>Oncology, 2003-01, Vol.64 (4), p.300-305</ispartof><rights>2003 S. Karger AG, Basel</rights><rights>2003 INIST-CNRS</rights><rights>Copyright 2003 S. Karger AG, Basel</rights><rights>Copyright (c) 2003 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-eccfe6533829e3b793030a2148dac318f25bc4eb619f62e9d4f71d6f550b3d7a3</citedby><cites>FETCH-LOGICAL-c385t-eccfe6533829e3b793030a2148dac318f25bc4eb619f62e9d4f71d6f550b3d7a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14749979$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12759524$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Petrioli, Roberto</creatorcontrib><creatorcontrib>Pozzessere, Daniele</creatorcontrib><creatorcontrib>Messinese, Simona</creatorcontrib><creatorcontrib>Sabatino, Marianna</creatorcontrib><creatorcontrib>Di Palma, Teresa</creatorcontrib><creatorcontrib>Marsili, Stefania</creatorcontrib><creatorcontrib>Correale, Pierpaolo</creatorcontrib><creatorcontrib>Manganelli, Antonio</creatorcontrib><creatorcontrib>Salvestrini, Francesco</creatorcontrib><creatorcontrib>Francini, Guido</creatorcontrib><title>Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy</title><title>Oncology</title><addtitle>Oncology</addtitle><description>Objective: The aim of this study was to evaluate the activity and tolerability of docetaxel in patients with hormone-resistant prostate cancer previously exposed to chemotherapy. Methods: We enrolled 27 patients with hormone-resistant prostatic cancer that had progressed during first-line chemotherapy. The primary end-point was palliative response defined as a 2-point reduction in the 6-point present pain intensity scale, and an improvement in Karnofsky performance status of one 10-point category. The treatment consisted of weekly docetaxel 25 mg/m² body surface area administered by means of a 1-hour intravenous infusion with corticosteroid premedication. Results: The primary criterion of palliative response was met in 13 patients (48%) after eight treatment cycles; its median duration was 6 months (range 1–8). Mean global quality of life improved in 8 and 10 patients after respectively four and eight treatment cycles. After a median follow-up of 8 months, 21 patients had died: the median survival was 9+ months (range 2–18). Weekly docetaxel was very well tolerated: grade 3 neutropenia occurred in 1 patient and grade 3 anemia in 2. Conclusions: Weekly low-dose docetaxel is an effective and well-tolerated treatment for patients with hormone-resistant prostate cancer previously exposed to chemotherapy.</description><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Phytogenic - administration & dosage</subject><subject>Antineoplastic Agents, Phytogenic - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Clinical Study</subject><subject>Drug Administration Schedule</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Paclitaxel - administration & dosage</subject><subject>Paclitaxel - adverse effects</subject><subject>Paclitaxel - analogs & derivatives</subject><subject>Palliative Care - methods</subject><subject>Pharmacology. Drug treatments</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Quality of Life</subject><subject>Taxoids</subject><subject>Treatment Outcome</subject><issn>0030-2414</issn><issn>1423-0232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0EtrGzEUBWBREhrX7aLrQBCGLrKYVM95LMPkCYaE0tLloJGukvFjNJVkN_73kWMn2UQbCe7HEfcg9J2SM0pl9ZOkUxBWyk9oRAXjGWGcHaARIZxkTFBxhL6EMNsqKfLP6IiyQlaSiREKfwHmiw2euv_ZhQuAL5yGqJ5ggbsen5u16jUYfOP80vWQ_YLQhaj6iO-9S48IuN4Kj-9V7KCPIQ1g3blVSKGXT0OKNDg6XD_C0sVH8GrYfEWHVi0CfNvfY_Tn6vJ3fZNN765v6_NppnkpYwZaW8gl5yWrgLdFxdM6ilFRGqU5LS2TrRbQ5rSyOYPKCFtQk1spSctNofgYTXa5g3f_VhBiM3Mr36cvG8ZIKVhBZUKnO6TTQsGDbQbfLZXfNJQ023abt3aTPdkHrtolmHe5rzOBH3ugglYL61M3XXh3ohBVlRYZo-Odmyv_AP4NvH4z-XB6V09fQDMYy58B-kuWlw</recordid><startdate>20030101</startdate><enddate>20030101</enddate><creator>Petrioli, Roberto</creator><creator>Pozzessere, Daniele</creator><creator>Messinese, Simona</creator><creator>Sabatino, Marianna</creator><creator>Di Palma, Teresa</creator><creator>Marsili, Stefania</creator><creator>Correale, Pierpaolo</creator><creator>Manganelli, Antonio</creator><creator>Salvestrini, Francesco</creator><creator>Francini, Guido</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope></search><sort><creationdate>20030101</creationdate><title>Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy</title><author>Petrioli, Roberto ; Pozzessere, Daniele ; Messinese, Simona ; Sabatino, Marianna ; Di Palma, Teresa ; Marsili, Stefania ; Correale, Pierpaolo ; Manganelli, Antonio ; Salvestrini, Francesco ; Francini, Guido</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-eccfe6533829e3b793030a2148dac318f25bc4eb619f62e9d4f71d6f550b3d7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Phytogenic - administration & dosage</topic><topic>Antineoplastic Agents, Phytogenic - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Clinical Study</topic><topic>Drug Administration Schedule</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Paclitaxel - administration & dosage</topic><topic>Paclitaxel - adverse effects</topic><topic>Paclitaxel - analogs & derivatives</topic><topic>Palliative Care - methods</topic><topic>Pharmacology. Drug treatments</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Quality of Life</topic><topic>Taxoids</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Petrioli, Roberto</creatorcontrib><creatorcontrib>Pozzessere, Daniele</creatorcontrib><creatorcontrib>Messinese, Simona</creatorcontrib><creatorcontrib>Sabatino, Marianna</creatorcontrib><creatorcontrib>Di Palma, Teresa</creatorcontrib><creatorcontrib>Marsili, Stefania</creatorcontrib><creatorcontrib>Correale, Pierpaolo</creatorcontrib><creatorcontrib>Manganelli, Antonio</creatorcontrib><creatorcontrib>Salvestrini, Francesco</creatorcontrib><creatorcontrib>Francini, Guido</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><jtitle>Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Petrioli, Roberto</au><au>Pozzessere, Daniele</au><au>Messinese, Simona</au><au>Sabatino, Marianna</au><au>Di Palma, Teresa</au><au>Marsili, Stefania</au><au>Correale, Pierpaolo</au><au>Manganelli, Antonio</au><au>Salvestrini, Francesco</au><au>Francini, Guido</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy</atitle><jtitle>Oncology</jtitle><addtitle>Oncology</addtitle><date>2003-01-01</date><risdate>2003</risdate><volume>64</volume><issue>4</issue><spage>300</spage><epage>305</epage><pages>300-305</pages><issn>0030-2414</issn><eissn>1423-0232</eissn><abstract>Objective: The aim of this study was to evaluate the activity and tolerability of docetaxel in patients with hormone-resistant prostate cancer previously exposed to chemotherapy. Methods: We enrolled 27 patients with hormone-resistant prostatic cancer that had progressed during first-line chemotherapy. The primary end-point was palliative response defined as a 2-point reduction in the 6-point present pain intensity scale, and an improvement in Karnofsky performance status of one 10-point category. The treatment consisted of weekly docetaxel 25 mg/m² body surface area administered by means of a 1-hour intravenous infusion with corticosteroid premedication. Results: The primary criterion of palliative response was met in 13 patients (48%) after eight treatment cycles; its median duration was 6 months (range 1–8). Mean global quality of life improved in 8 and 10 patients after respectively four and eight treatment cycles. After a median follow-up of 8 months, 21 patients had died: the median survival was 9+ months (range 2–18). Weekly docetaxel was very well tolerated: grade 3 neutropenia occurred in 1 patient and grade 3 anemia in 2. Conclusions: Weekly low-dose docetaxel is an effective and well-tolerated treatment for patients with hormone-resistant prostate cancer previously exposed to chemotherapy.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>12759524</pmid><doi>10.1159/000070285</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0030-2414 |
| ispartof | Oncology, 2003-01, Vol.64 (4), p.300-305 |
| issn | 0030-2414 1423-0232 |
| language | eng |
| recordid | cdi_karger_primary_70285 |
| source | Karger Journals; MEDLINE |
| subjects | Aged Antineoplastic agents Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - adverse effects Biological and medical sciences Chemotherapy Clinical Study Drug Administration Schedule Humans Infusions, Intravenous Male Medical sciences Middle Aged Paclitaxel - administration & dosage Paclitaxel - adverse effects Paclitaxel - analogs & derivatives Palliative Care - methods Pharmacology. Drug treatments Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Quality of Life Taxoids Treatment Outcome |
| title | Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T11%3A40%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Weekly%20Low-Dose%20Docetaxel%20in%20Advanced%20Hormone-Resistant%20Prostate%20Cancer%20Patients%20Previously%20Exposed%20to%20Chemotherapy&rft.jtitle=Oncology&rft.au=Petrioli,%20Roberto&rft.date=2003-01-01&rft.volume=64&rft.issue=4&rft.spage=300&rft.epage=305&rft.pages=300-305&rft.issn=0030-2414&rft.eissn=1423-0232&rft_id=info:doi/10.1159/000070285&rft_dat=%3Cproquest_karge%3E669586331%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220842715&rft_id=info:pmid/12759524&rfr_iscdi=true |